To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Liposomal daunorubicin is a chemotherapy drug that is FDA approved to treat AIDS-related Kaposi's sarcoma. It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma. Liposomal daunorubicin is intravenously administered. It utilizes the liposomal carrier system that provides a favorable pharmacokinetic profile at the site of KS lesions resulting in a 10-fold increase in concentrations compared to that which is achieved with conventional preparations.
Additional recommended knowledge
Trade name: DaunoXome®
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Liposomal_daunorubicin". A list of authors is available in Wikipedia.|